US › Healthcare

Mineralys Therapeutics, Inc. Common Stock (MLYS)

US · Healthcare · Biotechnology

$26.50+2.79%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-39.3M
Profit YoY
+6.8%
EPS
$-0.47
EPS estimate
$-0.44

EPS came in at -0.47 against a street estimate of -0.44 — a miss of 6.8%.

Key statistics

Market cap
$2.25B
Forward P/E
0.0
P/B
3.53
Book value
$7.74
EPS (TTM)
$-1.97
52-week high
$47.65
52-week low
$12.59
50-day MA
$27.00
200-day MA
$31.53
Beta
0.65

Analyst view

Analysts rate Mineralys Therapeutics, Inc. Common Stock a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $49.00.

Shareholding

Insiders
0.56%
Institutions
108.11%

Largest institutional holders

FundStake
Catalys Pacific LLC8.97%
RA Capital Management, LLC8.73%
Samsara BioCapital, LLC6.66%
FMR Inc5.51%
BlackRock Inc5.08%
Wellington Management Company LLP3.81%
State Street Corp3.33%
Caligan Partners LP3.15%

Recent filings & reports

DocumentDate
Company announcement · Q2 20262026-06-03
Material agreement · Q2 20262026-06-03
Shareholder vote results · Q2 20262026-05-22
Quarterly report · Q1 20262026-05-06
Results announced · Q2 20262026-05-06
Proxy statement · Q2 20262026-04-08
Annual report FY20252026-03-12
Quarterly report · Q3 20252025-11-10

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Mineralys Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.